Clinical Report: Ralinepag in pulmonary arterial hypertension
Overview
In the phase 3 ADVANCE OUTCOMES trial, ralinepag significantly reduced the incidence of first clinical worsening events in patients with pulmonary arterial hypertension compared to placebo. Ralinepag was associated with changes in N-terminal pro-B-type natriuretic peptide concentrations and 6-minute walk distance.
Background
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated pulmonary artery pressure, leading to significant morbidity and mortality. Effective treatment options are crucial for improving patient outcomes and quality of life.
Data Highlights
Outcome
Ralinepag
Placebo
First clinical worsening event
18%
36%
Disease progression
3%
11%
Initiation of parenteral or inhaled therapy
3%
7%
Unsatisfactory long-term clinical response
4%
10%
Mean 6MWD change
+8 m
-12 m
Key Findings
Ralinepag reduced the first clinical worsening event rate to 18% compared to 36% for placebo.
Only 3% of patients on ralinepag experienced disease progression versus 11% on placebo.
At week 28, N-terminal pro-B-type natriuretic peptide concentrations decreased by 4% with ralinepag, while increasing by 26% with placebo.
The mean 6-minute walk distance improved by 8 m in the ralinepag group compared to a decrease of 12 m in the placebo group.
Adverse events led to treatment discontinuation in 19% of ralinepag patients compared to 3% in the placebo group.
Clinical Implications
Clinicians should evaluate treatment options for PAH based on the findings of the ADVANCE OUTCOMES trial.
Conclusion
Ralinepag demonstrates significant efficacy in reducing clinical worsening events in patients with PAH compared to placebo.
A systematic review and meta-analysis found small, consistent reductions in craving across substance use disorders, while evidence for withdrawal symptoms and substance dependence remained limited.
A recent Perspective offered a speculative mechanistic argument for acupuncture’s potential role as an adjunctive strategy in neuroinfectious diseases.
